Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase

Abstract

Purchase $39.95

---

Highlights

•

A promising approach to treat ovarian cancer is oncolytic virus therapy using measles vaccine virus (MeV).

•

Arming of MeV with a prodrug-converting suicide-gene in combination with prodrug treatment highly enhanced ovarian cancer cell killing.

•

Virotherapy of ovarian cancer using armed measles vaccine virus warrants further clinical investigation.

---

Conclusions

With respect to safety and therapeutic impact, arming of oncolytic measles vaccine virus warrants further clinical investigation for ovarian cancer treatment.